Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

Journal

NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676

Informations de publication

Date de publication:
Aug 2022
Historique:
medline: 1 8 2022
pubmed: 1 8 2022
entrez: 6 2 2024
Statut: ppublish

Résumé

Tremelimumab/Durvalumab for Hepatocellular CarcinomaThis trial examined overall survival (OS) with tremelimumab plus durvalumab, durvalumab alone, or sorafenib in untreated patients with hepatocellular cancer who were not candidates for locoregional therapy. Median OS increased significantly by 2.5 months (16.4 vs. 13.8) with single-dose tremelimumab plus durvalumab treatment every 4 weeks versus sorafenib alone.

Identifiants

DOI: 10.1056/EVIDoa2100070 PMID: 38319892
pubmed: 38319892
doi: 10.1056/EVIDoa2100070
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

EVIDoa2100070

Auteurs

Ghassan K Abou-Alfa (GK)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Weill Medical College, Cornell University, New York.

George Lau (G)

Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong Special Administrative Region, China.

Masatoshi Kudo (M)

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.

Stephen L Chan (SL)

State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.

Robin Kate Kelley (RK)

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.

Junji Furuse (J)

Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Japan.

Wattana Sukeepaisarnjaroen (W)

Department of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.

Yoon-Koo Kang (YK)

Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.

Tu Van Dao (T)

Cancer Research and Clinical Trials Center, Department of Optimal Therapy, National Cancer Hospital, Hanoi, Vietnam.

Enrico N De Toni (EN)

Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich, Germany.

Lorenza Rimassa (L)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan.
Humanitas Cancer Center, Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano, Milan.

Valeriy Breder (V)

Chemotherapy Department No. 17, N.N. Blokhin Russian Cancer Research Center, Moscow.

Alexander Vasilyev (A)

Department of Oncology, Railway Clinical Hospital, St. Petersburg, Russia.

Alexandra Heurgué (A)

Department of Hepato-Gastroenterology, Robert-Debré Hospital, Reims, France.

Vincent C Tam (VC)

Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.

Kabir Mody (K)

Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL.

Satheesh Chiradoni Thungappa (SC)

Sri Venkateshwara Hospital, Bangalore, India.

Yuriy Ostapenko (Y)

Department of Minimally Invasive and Endoscopic Surgery, Interventional Radiology, National Cancer Institute, Kiev, Ukraine.

Thomas Yau (T)

Queen Mary Hospital, Pok Fu Lam, Hong Kong Special Administrative Region, China.

Sergio Azevedo (S)

Unidade de Pesquisa em Oncologia Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

María Varela (M)

Liver Unit, Hospital Universitario Central de Asturias, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias-Obra Social Cajastur, Instituto de Investigación Sanitaria del Principado de Asturias, Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturia, Oviedo, Spain.

Ann-Lii Cheng (AL)

National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan.

Shukui Qin (S)

People's Liberation Army Cancer Center, Nanjing Bayi Hospital, Nanjing, China.

Peter R Galle (PR)

University Medical Center, Mainz, Germany.

Sajid Ali (S)

AstraZeneca, Gaithersburg, MD.

Michelle Marcovitz (M)

AstraZeneca, Gaithersburg, MD.

Mallory Makowsky (M)

AstraZeneca, Gaithersburg, MD.

Philip He (P)

AstraZeneca, Gaithersburg, MD.

John F Kurland (JF)

AstraZeneca, Gaithersburg, MD.

Alejandra Negro (A)

AstraZeneca, Gaithersburg, MD.

Bruno Sangro (B)

Liver Unit and Hepato-pancreato-Biliary Oncology Area, Clínica Universidad de Navarra and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Pamplona, Spain.

Classifications MeSH